FDA grants priority review to Genentech’s bispecific antibody glofitamab for people with relapsed or refractory large B-cell lymphoma

Genentech

5 January 2023 - Results from the pivotal Phase 1/2 NP30179 study showed glofitamab induced durable response rates in people with heavily pretreated large B-cell lymphoma, with 40% achieving a complete response.

Genentech today announced that the US FDA has accepted the company’s biologics license application and granted priority review for glofitamab, an investigational CD20xCD3 T-cell engaging bispecific antibody, for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

Read Genentech press release

Michael Wonder

Posted by:

Michael Wonder